Multicenter phase II Trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 25, 2005, Pages 6019-6026

  Ibrahim, Nuhad K ^a   Samuels, Brian ^a   Page, Ray ^a   Doval, Dinesh ^a   Patel, Kirtikumar M ^a   Rao, S C ^a   Nair, Madhavan Krishnan ^a   Bhar, Paul ^a   Desai, Neil ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTHRACYCLINE; DOCETAXEL; PACLITAXEL; ALBUMINOID;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SENSORY NEUROPATHY; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; DISEASE COURSE; DRUG HYPERSENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ALBUMINS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 24944505659     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.013     Document Type: Article

References (35)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Ellis MJ, Hayes DF, Lippman ME: Treatment of metastatic breast cancer, in JR Harris, ME Lippman, M Morrow, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 749-798
3. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996
4. Taxol (paclitaxel) injection [package insert]. Princeton, NJ, Bristol-Myers Squibb Co, 2003
5. Gelderblom H, Verweij J, Nooter K, et al: Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598, 2001
6. Lorenz W, Reimann HJ, Schmal A, et al: Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent. Agents Actions 7:63-67, 1977
7. Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
8. Kloover JS, den Bakker MA, Gelderblom H, et al: Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br J Cancer 90:304-305, 2004
9. Sparreboom A, van Zuylen L, Brouwer E, et al: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 59:1454-1457, 1999
10. John TA, Vogel SM, Tiruppathi C, et al: Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284:L187-L196, 2003
11. Ibrahim NK, Desai N, Legha S, et al: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044, 2002
12. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979, Offset Publication No. 48
13. Simon R: How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079-1085, 1987
14. Taxotere (docetaxel) injection concentrate [package insert]. Bridgewater, NJ, Aventis Pharmaceutical Products, Inc, 2003
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Blum JL, Savin G, Edelman JE, et al: Long-term disease control in taxane-refractory metastatic breast cancer treated with nab-paclitaxel. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
17. Nyman DW, Campbell KJ, Patrick K, et al: A phase I trial of ABI-007 administered weekly for 3 doses every 4 weeks in patients with advanced non-hematologic malignancies. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
18. Desai N, Trieu V, Yao R, et al: Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: Role of a novel albumin transporter mechanism. The 26th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 348)
19. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. The 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 16-19, 1998 (abstr 388)
20. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
21. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411, 1999
22. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
23. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
24. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, et al: Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study. Proc Am Soc Clin Oncol 22:7, 2003 (abstr 25)
25. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18:724-733, 2000
26. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
27. Desai N, Yao Z, Soon-Shiong P, et al: Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle (ABI-007) and Taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel. The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002 (abstr462)
28. O'Shaughnessy J, Tjulandin S, Davidson N, et al: ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel, demonstrates superior efficacy vs taxol in MBC: A phase III trial. The 26th Annual Meeting of the San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003 (abstr 44)
29. Capri G, Munzone E, Tarenzi E, et al: Optic nerve disturbances: A new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86:1099-1101, 1994
30. Sparreboom A, Verweij J, van der Burg ME, et al: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4:1937-1942, 1998
31. Carver LA, Schnitzer JE: Caveolae: Mining little caves for new cancer targets. Nat Rev Cancer 3:571-581, 2003
32. Schubert W, Frank PG, Razani B, et al: Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 276:48619-48622, 2001
33. Tahir SA, Ren C, Timme TL, et al: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9:3653-3659, 2003
34. Yang G, Truong LD, Timme TL, et al: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873-1880, 1998
35. Yoo S-H, Park YS, Kim H-R, et al: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42:195-202, 2003